Zanzalintinib is an investigational oral agent that inhibits tyrosine kinase receptors associated with cancer growth, including TYRO3, VEGF, MET, AXL, and MER.
An ABC host has announced his retirement after an incredible career spanning more than 30 years.
CompagOS has produced biologically reproducible Bon3OID™ bone models using 3D bioprinting. Find out more in the interview!
Very few patients have left Gaza on the first day of opening, as critics say 'no information, no promises' from Israel.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results